Adoptive cell transfer immunotherapy for patients with solid epithelial cancers

Area of Science:

• Oncology
• Immunology
• Cancer Genomics

Background:

• Common epithelial cancers often express unique mutation-specific antigens.
• Tumor-infiltrating lymphocytes (TILs) reactive to these antigens are present in most patients.
• Adoptive cell transfer (ACT) is an emerging immunotherapy strategy.

Purpose of the Study:

• To investigate the potential of ACT immunotherapy for common epithelial cancers.
• To leverage patient-specific lymphocytes targeting cancer neoantigens.
• To evaluate early clinical responses to this targeted approach.

Main Methods:

• Identification of tumor mutation-specific antigens in common epithelial cancers.
• Isolation and expansion of autologous lymphocytes reactive to these antigens.
• Administration of expanded lymphocytes as ACT immunotherapy.

Main Results:

• Demonstration of lymphocyte reactivity against cancer mutation products in the majority of patients.
• Promising early outcomes from initial ACT immunotherapy trials targeting these specific antigens.

Conclusions:

• ACT immunotherapy holds significant potential for treating common epithelial cancers.
• Targeting patient-specific neoantigens with autologous lymphocytes is a viable strategy.
• Further clinical investigation is warranted to optimize ACT for broader application.